A novel role of IL-22R1 as a possible driver of inflammation in ALK+ anaplastic large cell lymphoma

被引：0
|
作者：
Savan, Ram [1 ]
Reynolds, Della A. [1 ]
McFarland, Adelle P. [1 ]
Feigenbaum, Lionel [2 ]
Ramakrishnan, Karthika [1 ]
Shirota, Hidekazu [1 ]
Klinman, Dennis M. [1 ]
Dunleavy, Kieron [3 ]
Pittaluga, Stefania [4 ]
Anderson, Stephen K. [1 ]
Donnelly, Raymond P. [5 ]
Wilson, Wyndham H. [3 ]
Young, Howard [1 ]
机构：
[1] NCI, Canc & Inflammat Program, Ctr Canc Res, Frederick, MD 21702 USA
[2] NCI, Lab Anim Sci Program, Ctr Canc Res, Frederick, MD 21702 USA
[3] NCI, Metab Branch, Lymphoma Therapeut Sect, Ctr Canc Res, Bethesda, MD 20892 USA
[4] NCI, Pathol Lab, Hematopathol Sect, Ctr Canc Res, Bethesda, MD 20892 USA
[5] US FDA, Div Therapeut Prot, Ctr Drug Evaluat & Res, Bethesda, MD 20892 USA
来源：
CYTOKINE | 2010年 / 52卷 / 1-2期
关键词：
D O I：
10.1016/j.cyto.2010.07.291
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：69 / 69
页数：1
相关论文
共 50 条
  • [1] A novel role for IL-22R1 as a driver of inflammation
    Savan, Ram
    McFarland, Adelle P.
    Reynolds, Della A.
    Feigenbaum, Lionel
    Ramakrishnan, Karthika
    Karwan, Megan
    Shirota, Hidekazu
    Klinman, Dennis M.
    Dunleavy, Kieron
    Pittaluga, Stefania
    Anderson, Stephen K.
    Donnelly, Raymond P.
    Wilson, Wyndham H.
    Young, Howard A.
    BLOOD, 2011, 117 (02) : 575 - 584
  • [2] Role of miRNAs in ALK+ and ALK- anaplastic large cell lymphoma
    Hamacher, F.
    Laimer, D.
    Scheideler, M.
    Trajanoski, Z.
    Egger, G.
    Kenner, L.
    Greil, R.
    Merkel, O.
    ONKOLOGIE, 2010, 33 : 209 - 209
  • [3] Pathobiology of ALK+ anaplastic large-cell lymphoma
    Amin, Hesham M.
    Lai, Raymond
    BLOOD, 2007, 110 (07) : 2259 - 2267
  • [4] Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma
    Bard, J. Dien
    Gelebart, P.
    Anand, M.
    Amin, H. M.
    Lai, R.
    LEUKEMIA, 2008, 22 (08) : 1595 - 1603
  • [5] Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma
    J Dien Bard
    P Gelebart
    M Anand
    H M Amin
    R Lai
    Leukemia, 2008, 22 : 1595 - 1603
  • [6] Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma
    Atabay, Elif Karaca
    Mecca, Carmen
    Wang, Qi
    Ambrogio, Chiara
    Mota, Ines
    Prokoph, Nina
    Mura, Giulia
    Martinengo, Cinzia
    Patrucco, Enrico
    Leonardi, Giulia
    Hossa, Jessica
    Pich, Achille
    Mologni, Luca
    Gambacorti-Passerini, Carlo
    Brugieres, Laurence
    Geoerger, Birgit
    Turner, Suzanne D.
    Voena, Claudia
    Cheong, Taek-Chin
    Chiarle, Roberto
    BLOOD, 2022, 139 (05) : 717 - 731
  • [7] ALK+ small cell variant of anaplastic large cell lymphoma with leukemic presentation
    Jiang, Xianyong
    Zhou, Daobin
    BLOOD, 2018, 131 (15) : 1764 - 1764
  • [8] ALK+ anaplastic large T-cell lymphoma, small cell variant
    André-Kerneïs, E
    Atassi-Abarah, W
    Ammar, NA
    Soussain, C
    Jeandel, R
    Allard, C
    Vincenot, A
    ANNALES DE BIOLOGIE CLINIQUE, 2002, 60 (01) : 85 - 88
  • [9] The role of the IL-22/IL-22R1 axis in cancer
    Lim, Chrissie
    Sayan, Ram
    CYTOKINE & GROWTH FACTOR REVIEWS, 2014, 25 (03) : 257 - 271
  • [10] Crizotinib, a Novel Inhibitor of ALK, Induces Apoptosis and Down Regulation of pSTAT3 in ALK+ Anaplastic Large Cell Lymphoma
    Hamedani, F. Saei
    Mo, Z.
    Amin, H. M.
    Cervania, M. A.
    Alkan, S.
    MODERN PATHOLOGY, 2013, 26 : 359A - 359A
12345